2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-amine | 1353569-74-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-amine
• 英文别名: 2-ethyl-4,5,6,7-tetrahydroindazol-3-amine
• CAS: 1353569-74-0
• 化学式: C₉H₁₅N₃
• 分子量: 165.238
• InChiKey: SCUQGWFBZXALTI-UHFFFAOYSA-N

物化性质

• 沸点：
  331.5±42.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 储存条件：
  存储条件：2-8°C，避光，惰性气体保护。

反应信息

• 作为反应物：
  描述：

  2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-amine 在 potassium carbonate 作用下， 以 甲醇 、 乙醇 、 丙酮 为溶剂， 反应 54.0h， 生成 N-(2-ethyl-4,5,6,7-tetrahydroindazol-3-yl)-4-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1,3-thiazol-2-amine
  参考文献：
  名称：

  Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators

  摘要：

  The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of Aβ42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting Aβ42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced Aβ42 levels in the plasma of J20 mice, in addition to reducing Aβ42 levels in the plasma and brain of Tg2576 mice.

  DOI：

  10.1016/j.bmc.2020.115734
• 作为产物：
  描述：

  乙基肼 、 2-氧代环己烷甲腈 以 乙醇 为溶剂， 反应 20.0h， 生成 2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-amine
  参考文献：
  名称：

  [EN] COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS
  [FR] COMPOSÉS ET LEURS UTILISATIONS DANS LA MODULATION DES NIVEAUX DE DIFFÉRENTES ALLOFORMES DU PEPTIDE AMYLOÏDE BÊTA

  摘要：

  公开号：

  WO2011163636A3

文献信息

• 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20150246923A1

  公开（公告）日：2015-09-03

  The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a , A, B 1 , B 2 , G, X 1 , Y 1 , Y 2 , and Y 3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供了代表为式I的替代的9H-嘧啶并[4,5-b]吲哚和5H-吡啶并[4,3-b]吲哚及相关类似物的药用可接受的盐、水合物和溶剂合物，其中R1a、A、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用式I的化合物来治疗对BET溴结构域抑制敏感的状况或疾病。本公开的化合物特别适用于治疗癌症。
• Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme
  作者：Kevin D. Rynearson、Ronald N. Buckle、Keith D. Barnes、R. Jason Herr、Nicholas J. Mayhew、William D. Paquette、Samuel A. Sakwa、Phuong D. Nguyen、Graham Johnson、Rudolph E. Tanzi、Steven L. Wagner

  DOI：10.1016/j.bmcl.2016.07.011

  日期：2016.8

  The design and construction of a series of novel aminothiazole-derived gamma-secretase modulators is described. The incorporation of heterocyclic replacements of the terminal phenyl D-ring of lead compound 1 was conducted in order to align potency with favorable drug-like properties. gamma-Secretase modulator 28 displayed good activity for in vitro inhibition of Abeta42, as well as substantial improvement

  描述了一系列新颖的氨基噻唑衍生的γ-分泌酶调节剂的设计和构建。进行铅化合物1的末端苯基D-环的杂环取代基的掺入，以使效力与有利的类药物性质对准。γ-分泌酶调节剂28表现出良好的体外抑制Abeta42活性，以及​​ADME和理化特性（包括水溶性）的显着改善。化合物28在小鼠中的药代动力学评估显示，其良好的大脑渗透能力以及良好的清除率，半衰期和分布体积共同支持了这类化合物的持续开发。
• COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS
  申请人：Wagner Steven L.

  公开号：US20130165416A1

  公开（公告）日：2013-06-27

  The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D)  (I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.

  本发明提供了一种新型化合物，其结构对应于公式（I）：（A）-（B）-（C）-（D）（I），或其药学上可接受的盐或前药，并提供其使用方法。
• 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10253044B2

  公开（公告）日：2019-04-09

  The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, A, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供了由式 I 表示的取代的 9H-嘧啶并[4,5-b]吲哚和 5H-嘧啶并[4,3-b]吲哚及相关类似物： 及其药学上可接受的盐、水合物和溶液，其中 R1a、A、B1、B2、G、X1、Y1、Y2 和 Y3 如说明书中所定义。本公开还涉及使用式 I 的化合物治疗对抑制 BET 溴链有反应的病症或紊乱。本公开的化合物特别适用于治疗癌症。
• 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20170210761A1

  公开（公告）日：2017-07-27

  The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a , A, B 1 , B 2 , G, X 1 , Y 1 , Y 2 , and Y 3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.